Concert Pharmaceuticals, Inc.
CNCEDelisted Mar 6, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001367920
Concert Pharmaceuticals, Inc. was delisted on Mar 6, 2023; its insiders filed their last Form 4 on Mar 6, 2023; 85 institutions reported holding it in 13F filings for Q4 2022, worth $207.2M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 85
- Q4 2022, +5 vs. previous quarter
- 13F value
- $207.2M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding CNCE, Q4 2022
No superinvestor reported holding CNCE at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by Concert Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 (view filing) | Feb 15 | 1 day | Stuart NancyChief Operating Officer | SSale | −6.05K | $8.33 | −$50.4K | −2.3%262.6K after | |
| Feb 16, 2023 (view filing) | Feb 15 | 1 day | Munsie Jeffrey AChief Legal Officer | SSale | −3.76K | $8.34 | −$31.4K | −4.1%88.0K after | |
| Feb 16, 2023 (view filing) | Feb 15 | 1 day | Cassella James VChief Development Officer | SSale | −3.76K | $8.34 | −$31.4K | −2.1%173.1K after | |
| Feb 16, 2023 (view filing) | Feb 15 | 1 day | Becker Marc A.Chief Financial Officer | SSale | −3.76K | $8.33 | −$31.3K | −2.9%123.9K after | |
| Jan 31, 2023 (view filing) | Jan 30 | 1 day | Stuart NancyChief Operating Officer | SSale | −13.2K | $8.35 | −$110.2K | −4.7%268.6K after | |
| Jan 31, 2023 (view filing) | Jan 30 | 1 day | Munsie Jeffrey AChief Legal Officer | SSale | −8.49K | $8.35 | −$70.9K | −8.5%91.8K after | |
| Jan 31, 2023 (view filing) | Jan 30 | 1 day | Cassella James VChief Development Officer | SSale | −10.1K | $8.35 | −$84.4K | −5.4%176.8K after | |
| Jan 31, 2023 (view filing) | Jan 30 | 1 day | Becker Marc A.Chief Financial Officer | SSale | −8.49K | $8.35 | −$70.9K | −6.2%127.6K after | |
| Jan 9, 2023 (view filing) | Jan 6 | 3 days | Tung Roger DChief Executive Officer | SSale | −9.24K | $7.24 | −$66.9K | −0.9%971.0K after | |
| Jan 9, 2023 (view filing) | Jan 6 | 3 days | Stuart NancyChief Operating Officer | SSale | −2.89K | $7.25 | −$21.0K | −1.0%281.8K after |
Top 10 13F holders, Q4 2022
The largest institutional positions in Concert Pharmaceuticals, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kynam Capital Management, LP | 4,420,349 | $25.8M | 3.96% | +2,747,308+164.2% | Added |
| BVF Inc | 3,629,000 | $21.2M | 0.89% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,910,984 | $11.2M | 0.00% | +69,214+3.8% | Added |
| Nantahala Capital Management, LLC | 1,732,388 | $10.1M | 0.91% | −54,771−3.1% | Reduced |
| Millennium Management LLC | 1,441,735 | $8.42M | 0.01% | +122,227+9.3% | Added |
| Citadel Advisors LLC | 1,391,302 | $8.13M | 0.01% | +269,873+24.1% | Added |
| Point72 Asset Management, L.P. | 1,340,300 | $7.83M | 0.03% | +1,069,700+395.3% | Added |
| Bank of America Corp | 1,308,386 | $7.64M | 0.00% | +4,391+0.3% | Added |
| Ingalls & Snyder LLC | 1,295,833 | $7.57M | 0.41% | −34,600−2.6% | Reduced |
| BlackRock Inc. | 1,236,951 | $7.22M | 0.00% | +410,760+49.7% | Added |